Faruqi and Faruqui, LLP Logo
Share this page

Vanda Pharmaceuticals, Inc. (VNDA)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm

NEW YORK, June 25, 2013 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA).

The investigation focuses on whether the Company and its executives violated federal securities laws with respect to its disclosures concerning business, operational, and compliance policies.  Specifically, the investigation focuses on whether Vanda misled investors regarding the efficacy of tasimelteon, one of the Company’s products, by manipulating aspects of tasimelteon’s primary Phase III study.

The Street published an article on June 19, 2013, questioning the efficacy of Vanda’s clinical trial procedure.  Following this news, the Company’s shares dropped $2.41 or over 22%.

Take Action

If you invested in Vanda’s stock or options between December 18, 2012 and June 18, 2013 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Vanda’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 06/25/2013

Class Period:

  • 12/18/2012 - 06/18/2013

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.